麦当劳公司高管近日表示,尽管GLP-1类减肥药物在市场上获得广泛关注,但截至目前的数据分析显示,这类药物的使用尚未对麦当劳的整体业务运营产生实质性影响。该高管强调,公司将持续关注健康饮食趋势对快餐行业带来的长期潜在变化,但当前业务表现仍保持稳定态势。
麦当劳公司高管近日表示,尽管GLP-1类减肥药物在市场上获得广泛关注,但截至目前的数据分析显示,这类药物的使用尚未对麦当劳的整体业务运营产生实质性影响。该高管强调,公司将持续关注健康饮食趋势对快餐行业带来的长期潜在变化,但当前业务表现仍保持稳定态势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.